Developing oral cancer drugs that block PI3K growth signals
PI3K helps cancer cells survive and grow, but also regulates insulin signaling and blood sugar. Blocking it can cause substantial side effects, complicating efforts to turn a promising cancer target into effective treatments.
Akylox Therapeutics is developing oral PI3K inhibitors for cancer treatment. Its approach combines several drug actions in one molecule, aiming to attack tumours while limiting effects on other tissues.
What stands out about Akylox Therapeutics
Holds exclusive rights to technology licensed from the University of Basel under a pharmaceutical patent-rights agreement.
Reports over DKK 32,600,000 in gross equity cash receipts from inception through December 2025, including completed cash capital increases.
Spun out of the University of Basel in 2024, originating from its Departments of Biomedicine and Chemistry.
Its founding project, led by Dennis Gillingham and Matthias Wymann, won the University of Basel’s third-edition Propelling Grant.
Co-founder Matthias Wymann previously founded PIQUR Therapeutics.
Co-founder Alexander Flohr previously co-founded Ridgeline Discovery and helped build Black Diamond and Monte Rosa.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.